U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06813222) titled 'Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin' on Sept. 20, 2024.
Brief Summary: Anemia-Related Outcomes in Patients with CKD Treated with Dapagliflozin
This study aims to identify factors that predict anemia improvement in chronic kidney disease (CKD) patients using Dapagliflozin, an SGLT2 inhibitor.
Key questions:
* What factors influence how well Dapagliflozin improves anemia in CKD patients?
* Are there specific characteristics that predict better responses to Dapagliflozin treatment?
The investigators will review medical records of CKD patients who started taking Dapagliflozin. The investigators wi...